SCHEMBL4506403

SCHEMBL4506403

OC(CCl)CN1CCOCC1

nearest known ligand 0.75

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.75
ATM Q13315 1/20 0.47
TSHR P16473 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CYP2D6 P10635 1/20 0.45
GAA P10253 1/20 0.45
MAPK1 P28482 1/20 0.45
POLB P06746 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 1/20 0.44
ANPEP P15144 1/20 0.44
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6550868 0.98 USP2 (0.72) USP2ATMTSHRL3MBTL1SMN1; SMN2
SCHEMBL11791414 0.88 USP2 (0.57) USP2ATMTSHRL3MBTL1SMN1; SMN2
SCHEMBL709506 0.86 USP2 (1.00) USP2ATMTSHRL3MBTL1SMN1; SMN2
SCHEMBL8391173 0.84 MEN1 (0.52) USP2ATMTSHRL3MBTL1SMN1; SMN2
SCHEMBL9819626 0.84 MEN1 (0.52) USP2ATMTSHRL3MBTL1SMN1; SMN2
SCHEMBL4384137 0.80 USP2 (0.78) USP2ATMTSHRL3MBTL1SMN1; SMN2
SCHEMBL11186 0.80 USP2 (0.78) USP2ATMTSHRL3MBTL1SMN1; SMN2
SCHEMBL4388837 0.80 USP2 (0.78) USP2ATMTSHRL3MBTL1SMN1; SMN2
SCHEMBL22470454 0.79 USP2 (0.56) USP2ATMTSHRSMN1; SMN2HSD17B10
SCHEMBL488808 0.79 MEN1 (0.68) USP2ATMTSHRSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7179910-B2 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors AGOURON PHARMACEUTICALS, INC. (US) 2007-02-20 US claimed
US-11186583-B2 5-alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidines for treatment of lymphoma UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2021-11-30 US disclosed
EP-3749670-B1 5-ALKYLTHIO-7-[(4-ARYLBENZYL)AMINO]-1(2)H-PYRAZOLO[4,3-D]PYRIMIDINES FOR TREATMENT OF LYMPHOMA UNIV PALACKEHO (CZ) 2021-10-06 EP disclosed
US-10889748-B2 Process for preparing dibenzylamine quaternary ammonium salt high-temperature resistant corrosion inhibitor and applications thereof SOUTHWEST PETROLEUM UNIVERSITY (CN) 2021-01-12 US disclosed
US-20200361943-A1 5-ALKYLTHIO-7-[(4-ARYLBENZYL)AMINO]-1(2)H-PYRAZOLO[4,3-D]PYRIMIDINES FOR TREATMENT OF LYMPHOMA UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2020-11-19 US disclosed
US-20200339865-A1 PROCESS FOR PREPARING DIBENZYLAMINE QUATERNARY AMMONIUM SALT HIGH-TEMPERATURE RESISTANT CORROSION INHIBITOR AND APPLICATIONS THEREOF SOUTHWEST PETROLEUM UNIVERSITY (CN) 2020-10-29 US disclosed
CN-111499596-A Preparation method of furaltadone hydrochloride 衢州伟荣药化有限公司 2020-08-07 CN disclosed
WO-2020082476-A1 PREPARATION METHOD FOR AND USE OF DIBENZYLAMINE QUATERNARY AMMONIUM SALT HIGH-TEMPERATURE RESISTANT ACIDIZING CORROSION INHIBITOR 西南石油大学 2020-04-30 WO disclosed
US-8513221-B2 PI3K isoform selective inhibitors Xcovery Holding, LLC (US) 2013-08-20 US disclosed
US-8513221-B2 PI3K isoform selective inhibitors Xcovery Holding, LLC (US) 2013-08-20 US disclosed
EP-1370554-A1 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS PHARMACIA & UPJOHN COMPANY (US) 2003-12-17 EP disclosed
US-6653308-B2 Anticancer agents; antidiabetic agents; antiinflammatory agents SUGEN, INC. 2003-11-25 US disclosed
US-20030130280-A1 Treatment of acute myeloid leukemia with indolinone compounds SUGEN, INC. 2003-07-10 US disclosed
US-20030092917-A1 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors SUGEN, INC. 2003-05-15 US disclosed
WO-2003035009-A2 TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS SUGEN, INC. (US) 2003-05-01 WO disclosed
WO-2002066463-A1 3-(4-AMIDOPYRROL-2-YLMETHLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS PHARMACIA & UPJOHN COMPANY (US) 2002-08-29 WO disclosed
US-5773437-A UROGENITAL DISORDERS SUCH AS DYSURIA NIPPON CHEMIPHAR CO., LTD. (JP) 1998-06-30 US disclosed
CN-1148853-A Alkylenediamine derivatives NIPPON CHEMIPHAR CO (JP) 1997-04-30 CN disclosed
EP-0753514-A1 ALKYLENEDIAMINE DERIVATIVE NIPPON CHEMIPHAR CO., LTD. (JP) 1997-01-15 EP disclosed
EP-0486211-A1 Isoquinoline derivatives CHINOIN Gyògyszer és Vegyészeti Termékek Gyára RT. (HU) 1992-05-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339865-A1 PROCESS FOR PREPARING DIBENZYLAMINE QUATERNARY AMMONIUM SALT HIGH-TEMPERATURE RESISTANT CORROSION INHIBITOR AND APPLICATIONS THEREOF ABL1, TYR, KCNN1 USP2 1781/4885ATM 946/4885TSHR 4427/4885
US-10889748-B2 Process for preparing dibenzylamine quaternary ammonium salt high-temperature resistant corrosion inhibitor and applications thereof ABL1, TYR, KCNN1 USP2 1781/4885ATM 946/4885TSHR 4427/4885
US-20200361943-A1 5-ALKYLTHIO-7-[(4-ARYLBENZYL)AMINO]-1(2)H-PYRAZOLO[4,3-D]PYRIMIDINES FOR TREATMENT OF LYMPHOMA TK1, DCK, CCNK USP2 2898/4885ATM 289/4885TSHR 3045/4885
US-20030130280-A1 Treatment of acute myeloid leukemia with indolinone compounds FLT3, FLI1, MCL1 USP2 4376/4885ATM 108/4885TSHR 2959/4885
US-20030092917-A1 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors PDPK1, MKNK1, PKN2 USP2 3652/4885ATM 259/4885TSHR 4437/4885
US-11186583-B2 5-alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidines for treatment of lymphoma TK1, DCK, CCNK USP2 2898/4885ATM 289/4885TSHR 3045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.